February 2017February 2017
New Product - Kyprolis
Kyprolis (carfilzomib) is a tetrapeptide epoxyketone proteasome inhibitor that selectively and irreversibly binds to the N-terminal threonine containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome, and displays little to no activity against other protease classes. Kyprolis, as part of combination therapy with dexamethasone, or lenalidomide and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. Kyprolis is available as a single use 30 mL vial containing 30 mg of carfilzomib or 50 mL vial containing 60 mg of carfilzomib in packs of 1’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au